|
Nuvalent, Inc. (NUVL) DCF -Bewertung
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Nuvalent, Inc. (NUVL) Bundle
Verbessern Sie Ihre Anlagestrategien mit dem DCF -Taschenrechner von Nuvalent, Inc. (NUVL)! Erforschen Sie reale Finanzdaten, passen Sie Wachstumsprognosen und -kosten an und beobachten Sie sofort, wie sich diese Modifikationen auf den inneren Wert von Nuvalent, Inc. (NUVL) auswirken.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | 2.3 | -45.8 | -86.1 | -126.2 | -280.4 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | 16.9 | .2 | -.4 | 23.3 | .0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -14.6 | -46.0 | -85.7 | -149.5 | -280.4 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 10.3 | 288.1 | 472.2 | 719.9 | 1,118.3 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | 1.3 | 2.9 | 7.2 | 9.3 | 5.2 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | -0.29386 | -0.29386 | -0.29386 | -0.29386 | -0.29386 | -0.29386 | -0.29386 | -0.29386 | -0.29386 | -0.29386 |
| EBITAT | -14.6 | -46.0 | -76.8 | -149.5 | -281.2 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | 3.6 | -44.2 | -72.9 | -124.1 | -285.2 | -5.2 | .0 | .0 | .0 | .0 |
| WACC, % | 10.55 | 10.55 | 10.55 | 10.55 | 10.55 | 10.55 | 10.55 | 10.55 | 10.55 | 10.55 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -4.7 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -5 | |||||||||
| Net Debt | -146 | |||||||||
| Equity Value | 141 | |||||||||
| Diluted Shares Outstanding, MM | 66 | |||||||||
| Equity Value Per Share | 2.12 |
What You Will Get
- Real Nuvalent Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures.
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Nuvalent’s fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections.
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility.
Key Features
- Comprehensive DCF Model: Features detailed unlevered and levered DCF valuation frameworks tailored for Nuvalent, Inc. (NUVL).
- WACC Tool: Pre-configured Weighted Average Cost of Capital calculator with adjustable parameters.
- Customizable Forecast Inputs: Adjust growth projections, capital investments, and discount rates as needed.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency metrics specific to Nuvalent, Inc. (NUVL).
- Visual Dashboard and Graphs: Graphical representations that highlight essential valuation indicators for straightforward analysis.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Nuvalent, Inc. (NUVL) data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Nuvalent, Inc. (NUVL)’s intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose This Calculator for Nuvalent, Inc. (NUVL)?
- Designed for Experts: A sophisticated tool utilized by industry analysts, CFOs, and strategic consultants.
- Accurate Financial Data: Nuvalent’s historical and projected financials are preloaded for precision.
- Flexible Scenario Analysis: Effortlessly simulate various forecasts and assumptions.
- Comprehensive Outputs: Automatically computes intrinsic value, NPV, and essential financial metrics.
- User-Friendly: Step-by-step guidance ensures a smooth user experience.
Who Should Use Nuvalent, Inc. (NUVL)?
- Biotech Students: Explore drug development processes and apply them to real-world case studies.
- Researchers: Integrate innovative models into your studies or clinical trials.
- Investors: Evaluate your investment strategies and analyze market performance for Nuvalent, Inc. (NUVL).
- Pharmaceutical Analysts: Enhance your analysis with a tailored, comprehensive model for drug valuation.
- Healthcare Entrepreneurs: Understand how biotech firms like Nuvalent, Inc. (NUVL) are assessed in the market.
What the Template Contains
- Historical Data: Includes Nuvalent, Inc.’s (NUVL) past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Nuvalent, Inc.’s (NUVL) intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital for Nuvalent, Inc. (NUVL).
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions for Nuvalent, Inc. (NUVL).
- Quarterly and Annual Statements: A complete breakdown of Nuvalent, Inc.’s (NUVL) financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically for Nuvalent, Inc. (NUVL).
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.